Research Triangle Park, NC (December 15, 2004) Study results published today in the journal Movement Disorders show that Requip(ropinirole HCl) Tablets effectively treats the symptoms of primary Restless Legs Syndrome (RLS) as assessed by improvements in symptoms, over 12 weeks. Improvements were seen as early as one week. The study of 267 patients, one of the largest placebo-controlled trials of a treatment for RLS conducted to-date, also showed significant improvements in sleep and quality of life in RLS patients taking Requip versus placebo. Requip is under review by the U.S. Food and Drug Administration (FDA) for the treatment of the signs and symptoms of primary RLS. There is no FDA-approved treatment for RLS in the United States.
"Patients with Restless Legs Syndrome often suffer from chronic sleep problems as a result of an urge to move their legs, often accompanied by discomfort or unpleasant feelings in their legs. This sleep disruption is one of the most distressing aspects of the condition and can greatly impact quality of life," said Arthur S. Walters, M.D., Director of the Center for Sleep Disorders Treatment, Research and Education at the New Jersey Neuroscience Institute at John F. Kennedy Medical Center. "These study results are encouraging because they provide evidence that Requip significantly improved symptoms of RLS at one week. Patients experienced improvements in sleep and quality of life."
Restless Legs Syndrome is a common and disruptive neurological condition characterized by an irresistible urge to move the legs and by uncomfortable or sometimes painful sensations in the legs often described as creeping-crawling, burning or twitching. Symptoms of RLS generally occur at rest, such as when sitting, lying or sleeping, and are temporarily relieved by movement. These symptoms can significantly disrupt a patient's sleep and daily activities. People with RLS often have difficulty falling and staying asleep and can feel Page: 1 2 3 4 Related medicine news :1
Contact: Christina Corso
Cohn & Wolfe
. GSKS Requip(R) (ropinirole HCl) significantly reduces periodic leg movements in patients with RLS2
. Millions wasted on blood pressure tablets3
. Biaxin XL (R) (Clarithromycin extended-release tablets) and Levaquin(R) achieve similar results for community-acquired pneumonia4
. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years5
. First head-to-head study to compare lidoderm patch and Celebrex in treating pain6
. Hormonal treatment improves survival in high-risk prostate cancer patients7
. Chronic pain treatments more effective when taken together, new study shows8
. Brain activity prior to treatment flags vulnerability to antidepressant side effects9
. Unexpected benefit seen in treating HER-2 breast cancer with new preoperative drug combo10
. OHSU scientists test medication to treat involuntary weight loss11
. Cultural and social factors influence prostate cancer treatment